[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2011093810A3 - Dry powder pharmaceutical composition comprising tiotropium and mometasone - Google Patents

Dry powder pharmaceutical composition comprising tiotropium and mometasone Download PDF

Info

Publication number
WO2011093810A3
WO2011093810A3 PCT/TR2011/000012 TR2011000012W WO2011093810A3 WO 2011093810 A3 WO2011093810 A3 WO 2011093810A3 TR 2011000012 W TR2011000012 W TR 2011000012W WO 2011093810 A3 WO2011093810 A3 WO 2011093810A3
Authority
WO
WIPO (PCT)
Prior art keywords
tiotropium
dry powder
mometasone
pharmaceutical composition
powder pharmaceutical
Prior art date
Application number
PCT/TR2011/000012
Other languages
French (fr)
Other versions
WO2011093810A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2010/00619A external-priority patent/TR201000619A2/en
Priority claimed from TR2010/00730A external-priority patent/TR201000730A2/en
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Publication of WO2011093810A2 publication Critical patent/WO2011093810A2/en
Publication of WO2011093810A3 publication Critical patent/WO2011093810A3/en
Priority to US13/531,972 priority Critical patent/US8834931B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to pharmaceutical compositions in dry powder form comprising tiotropium and mometasone furoate and/or their pharmaceutically acceptable derivatives as active agents, and capsule and blister forms containing these pharmaceutical compositions so as to be used in treatment of respiratory tract diseases.
PCT/TR2011/000012 2009-12-25 2011-01-28 Dry powder pharmaceutical composition comprising tiotropium and mometasone WO2011093810A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/531,972 US8834931B2 (en) 2009-12-25 2012-06-25 Dry powder formulation containing tiotropium for inhalation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
TR2010/00619A TR201000619A2 (en) 2010-01-28 2010-01-28 Pharmaceutical composition in dry powder form comprising tiotropium and mometasone.
TR2010/00619 2010-01-28
TR2010/00730 2010-02-02
TR2010/00730A TR201000730A2 (en) 2010-02-02 2010-02-02 Pharmaceutical composition in dry powder form comprising tiotropium and mometasone.

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000014 Continuation-In-Part WO2011093812A2 (en) 2009-12-25 2011-01-28 Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000011 Continuation-In-Part WO2011093809A2 (en) 2009-12-25 2011-01-28 Dry powder pharmaceutical composition comprising tiotropium and ciclesonide

Publications (2)

Publication Number Publication Date
WO2011093810A2 WO2011093810A2 (en) 2011-08-04
WO2011093810A3 true WO2011093810A3 (en) 2012-02-23

Family

ID=43899579

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000012 WO2011093810A2 (en) 2009-12-25 2011-01-28 Dry powder pharmaceutical composition comprising tiotropium and mometasone

Country Status (1)

Country Link
WO (1) WO2011093810A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107951893B (en) * 2016-10-18 2022-04-26 天津金耀集团有限公司 Mometasone furoate powder inhalant composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078743A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and mometasone
US20050123486A1 (en) * 2003-12-03 2005-06-09 Microdrug Ag Medical product containing tiotropium
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
WO2011078817A1 (en) * 2009-12-25 2011-06-30 Mahmut Bilgic Combination of tiotropium, mometasone and a cromoglicic acid derivative in dry powder form

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE8790T1 (en) 1981-02-02 1984-08-15 Schering Corporation AROMATIC HETEROCYCLIC STEROID ESTER, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE3931041C2 (en) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Esters of thienyl carboxylic acids with amino alcohols, their quaternization products, processes for their preparation and medicaments containing them
TR200803522A1 (en) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Easy to use inhalation device.
TR200803523A1 (en) 2008-05-16 2009-12-21 Bi̇lgi̇ç Mahmut Assembly with ribbon packaging

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078743A1 (en) * 2000-04-18 2001-10-25 Glaxo Group Limited Medical combinations comprising tiotropium and mometasone
US20090088408A1 (en) * 2001-06-23 2009-04-02 Meade Christopher J M Pharmaceutical compositions on anticholinergics, corticosteroids and betamimetics
US20050123486A1 (en) * 2003-12-03 2005-06-09 Microdrug Ag Medical product containing tiotropium
WO2011078817A1 (en) * 2009-12-25 2011-06-30 Mahmut Bilgic Combination of tiotropium, mometasone and a cromoglicic acid derivative in dry powder form

Also Published As

Publication number Publication date
WO2011093810A2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
IL223783B (en) Substituted 1-indole compound for use in the treatment of a disease or condition, a pharmaceutical composition comprising the compound and use of the compound for the preparation of a medicament
IL216741A (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating diseases
IL223795A (en) Tetrahydro-pyrido-pyrimidine derivatives, process for their preparation, pharmaceutical compositions comprising them and use thereof in the manufacture of medicaments
IL213019A (en) 1-aza-3-heteroaryl-azulene derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments
WO2013183062A3 (en) Palatable formulations of ibuprofen
WO2012021715A3 (en) Stable formulations of linaclotide
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
TR201000680A2 (en) Pharmaceutical compositions containing tiotropium, formoterol and budesonide
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
TR201000733A2 (en) Pharmaceutical compositions comprising fluticasone, tiotropium and sodium chromoglycate.
TR201000681A2 (en) Dry powder formulations inhaled.
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
MX2015015132A (en) Inhalable pharmaceutical compositions and the inhaler devices containing them.
WO2011093818A3 (en) Pharmaceutical compositions comprising salmeterol and fluticasone
WO2010042701A3 (en) Corticosteroid compositions for use in treating diseases of the upper and lower airway passages
WO2011101734A3 (en) Taste-masked powder for suspension compositions of methylprednisolone
WO2011093811A3 (en) Pharmaceutical preparations comprising formoterol and fluticasone
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
WO2011058245A8 (en) Novel mannopyranoside derivatives with anticancer activity
WO2011093812A3 (en) Pharmaceutical formulation comprising tiotropium and budesonide in dry powder form
WO2012030308A3 (en) Formulation comprising cellobiose
WO2011093814A3 (en) A pharmaceutical combination comprising formoterol and ciclesonide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11707730

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11707730

Country of ref document: EP

Kind code of ref document: A2